ALX Oncology, a clinical-stage immuno-oncology company, entered into a loan facility agreement with Oxford Finance and Silicon Valley Bank for up to $100 million of non-dilutive financing.
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy for all stages of cancer, closed a $125 million debt facility with Oxford Financial, of which $55 million is available immediately to repay the company’s existing $50 million of debt.
Oxford Finance closed a $30 million senior secured term loan with Selux Diagnostic, a Boston-based medical device company focused on personalized diagnostics to combat superbug infections and fight antibiotic resistance.
Oxford Finance closed a $50 million senior secured term loan with OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders.
Oxford Finance provided a $45 million senior secured loan facility to CENTOGENE, a commercial-stage company focused on generating data-driven insights to diagnose, understand and treat rare diseases.
Oxford Finance closed a $50 million senior secured term loan for Kezar Life Sciences, a clinical-stage biotechnology company discovering and developing treatments for immune-mediated and oncologic disorders.
Oxford Finance closed a $20 million senior secured term loan for PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology.
Viracta Therapeutics, a precision oncology company primarily focused on targeting virus-associated malignancies, entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance for up to $50 million.
4D pharma, a pharmaceutical company developing live biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, closed a senior secured credit facility for up to $30 million with Oxford Finance.
Oxford Finance closed a $125 million senior secured term loan with Kala Pharmaceuticals, a biopharmaceutical company focused on the discovery, development and commercialization of therapies for eye diseases.